On 1 April 2013 a two-judge bench of the Supreme Court dismissed Novartis's decade-long campaign for an Indian patent on the beta-crystalline form of Imatinib Mesylate — sold abroad as Glivec (and as Gleevec in the United States). The Court read *Section 3(d)* of the *Patents Act 1970* as a heightened patentability filter for incremental pharmaceutical claims, glossed 'efficacy' as 'therapeutic efficacy', and held that improvements in bioavailability, hygroscopicity and flow are physico-chemical attributes that do not, without more, cross the s.3(d) threshold. The judgment supplied the doctrinal architecture for India's post-TRIPS anti-evergreening regime and remains the anchoring authority on incremental-pharma patentability.